Thane Wettig
Net Worth
Last updated:
What is Thane Wettig net worth?
The estimated net worth of Mr. Thane Wettig is at least $7,822,082 as of 7 Mar 2024. He owns shares worth $5,124,940 as insider, has earned $365,022 from insider trading and has received compensation worth at least $2,332,120 in FibroGen, Inc..
What is the salary of Thane Wettig?
Mr. Thane Wettig salary is $583,030 per year as Chief Commercial Officer in FibroGen, Inc..
How old is Thane Wettig?
Mr. Thane Wettig is 60 years old, born in 1965.
What stocks does Thane Wettig currently own?
As insider, Mr. Thane Wettig owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| FibroGen, Inc. (FGEN) | Chief Commercial Officer | 470,178 | $10.9 | $5,124,940 |
What does FibroGen, Inc. do?
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Thane Wettig insider trading
FibroGen, Inc.
Mr. Thane Wettig has made 9 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he purchased 50,000 units of FGEN stock worth $95,450 on 7 Mar 2024.
The largest trade he's ever made was exercising 50,000 units of FGEN stock on 7 Mar 2024. As of 7 Mar 2024 he still owns at least 470,178 units of FGEN stock.
FibroGen key executives
FibroGen, Inc. executives and other stock owners filed with the SEC:
- Dr. Elias Kouchakji (69) Senior Vice President of Clinical Devel., Drug Safety & Pharmacovigilance
- Dr. Mark Eisner M.D., M.P.H. (59) Chief Medical Officer
- Mr. Enrique A. Conterno (58) Chief Executive Officer & Director
- Mr. James A. Schoeneck (67) Chairman
- Mr. Pat Cotroneo (61) Executive Advisor to Chief Executive Officer
- Mr. Thane Wettig (60) Chief Commercial Officer